Baker McKenzie and the Financial Times co-created a multimedia series, the FT Big Deal, to explore new trends shaping transactions and how to unlock value. In this series, Baker McKenzie lawyers are joined by industry thought leaders to discuss the key developments and issues shaping the future of global transactions.
With the annual J.P. Morgan Healthcare Conference pivoting to a virtual format again in 2022, we will be hosting a lineup of virtual events and reports aligned with the industry’s biggest conference.
Click to read Digital healthcare, a globally booming market, has been catalyzed by the events of COVID-19. In Asia Pacific, in particular, a rapidly expanding population, an empowered and tech-savvy middle class and physician shortage has created the perfect conditions for digital health innovation. A new era of digital healthcare…
With the healthcare and life sciences sector at the heart of the pandemic, we are seeing some new issues arising in the already complex world of life sciences collaborations, for both coronavirus-related and other products and therapies. The Life Sciences Collaborations: Key Considerations in the COVID-19 Era document is a…
Healthcare and life sciences is a robust market. Though it’s not immune to the economic and geopolitical headwinds affecting all industries, its underlying strength will continue to promote dealmaking. Following a robust 2018, dealmaking activity in the sector softened in 2019. Our Global Transactions Forecast, compiled in collaboration with Oxford Economics,…
Germany and Austria recently introduced new alternative merger control thresholds based on transaction value. At EU level the introduction of a value-based filing threshold is also being discussed.